Budesonide is considered a first-line treatment for mild to moderate Crohn's disease of the ileum and/or ascending colon. A study in the Journal of Crohn’s & Colitis details an eight-week, double-blind, double-dummy randomized trial comparing budesonide 9mg once-daily to budesonide 3mg three-times daily in 471 patients with mild-to-moderately active ileocolonic Crohn's disease. The primary endpoint of clinical remission defined as CDAI <150 at week eight in the research was statistically non-inferior in budesonide 9mg once-daily compared budesonide 3mg three-times daily. The rate of clinical remission was similar in both groups at all time points during the study, as was the mean time to remission (21.9 days vs. 21.4 days, respectively). Thus, budesonide at the recommended 9mg/day dose can be administered once a day without any loss of efficacy compared to the conventional three-time daily dose.
Oral budesonide 9 mg/day represents first-line treatment of mild-to-moderately active ileocolonic Crohn’s disease.